Movers
All Movers coverage
Novartis Miss in Myotonic Dystrophy Lands on Dyne Therapeutics, Which Built Its Accelerated-Approval Path on the Same Endpoint
Novartis said Tuesday that its Phase III HARBOR study of del-desiran failed to beat placebo on video hand opening time. Dyne's registrational expansion cohort in the same disease uses that exact measure as its primary endpoint, with topline data guided for the first quarter of 2027.
Alumis Loses Half Its Market Value After Lupus Trial Misses Overall, Hits in Interferon-High Subgroup
The 408-patient LUMUS study of envudeucitinib failed its primary BICLA endpoint across the whole enrolled population, and Alumis shares fell by more than half in Sept. 1 trading. The company says the interferon-high patients who did respond were unexpectedly under-represented in the trial, a defence that shifts the burden onto a Phase 3 that has not yet been designed.
Rezolve AI's First-Half Revenue Hits $130.8 Million, but Gross Margin Falls to 48.9% and Net Loss Widens to $139.5 Million
Revenue rose nearly 21-fold from a year earlier, yet gross margin dropped from 95.2% and the company burned $96.1 million of operating cash against $100.5 million of cash and restricted cash at June 30. Shares fell about 13% premarket Tuesday even as management reaffirmed roughly $360 million of full-year revenue guidance.
J.H. Whitney sells 15 million Aveanna shares at $11.75, a week after the company raised guidance. Aveanna receives none of the money.
The home-health provider announced the launch of the secondary offering on Aug. 20 and priced it at $11.75 a share, about 9.4% below Thursday's $12.97 close. The selling stockholders are affiliates of J.H. Whitney Equity Partners VII plus current and former directors and officers; RBC Capital Markets is sole book-running manager and settlement is expected on Aug. 24.
Capricor Jumps as the FDA Agrees to Look at 24-Month Duchenne Data. Agreeing to Look Is Not Approving.
CAPR gave back nearly half its premarket gain by early afternoon; by the company's account the FDA is willing to review an amendment and extend the clock, which says nothing about the outcome.
Globant Trims Its 2026 Outlook as North America Shrinks — and Points at a $52.8 Million AI Line to Explain Why It Isn't Worried
The $1.8 billion NYSE-listed IT services firm held revenue flat at $614.4 million and cut its full-year range for the first time this year. Shares were quoted about 13.6% lower in after-hours trade, against a Thursday close that was up 5.8%.
Leslie's Collapses, Harmonic and EnerSys Jump: Wednesday Night's Small-Cap Earnings Split Sets Up Thursday's Open
A pool retailer withdrew its outlook and said it is exploring strategic alternatives, while a broadband equipment maker and a battery supplier raised the bar. The dispersion beneath a steady small-cap index is the story heading into Thursday's PPI print.
Astronics, Velo3D and Definium all closed higher Wednesday for three unrelated reasons
An aerospace supplier posting record bookings, a metal 3D-printing company raising guidance, and a clinical-stage biotech clearing a Phase 3 endpoint all finished Wednesday higher. The mechanics behind each move have almost nothing in common.
Cava and H&R Block jump on results while Neurocrine and Performance Food Group slide
Wednesday's mid-cap tape split sharply along earnings lines, with two double-digit gainers on beats and raises and two decliners on a safety report and a narrow revenue miss.
Earnings Season Bites: OppFi and Purple Innovation Sink on Guidance Cuts While Plug Power and Riot Rally
Second-quarter results drove sharp two-way moves in smaller stocks Tuesday, with guidance cuts punished severely and beats rewarded with double-digit gains.